RESPIRATORY FAILURE and ARDS. By Laurie Dickson. Respiration. Exchange of O2 and CO2 gas exchange. Respiratory Failure the inability of the cardiac and pulmonary systems to maintain an adequate exchange of oxygen and CO2 in the lungs. Hypoxemic Respiratory Failure- (Affects the pO2).
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation
Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement.Téléchargez la présentation en cliquant sur ce lien.Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.
Respiration • Exchange of O2 and CO2 • gas exchange • Respiratory Failure • the inability of the cardiac and pulmonary systems to maintain an adequate exchange of oxygen and CO2 in the lungs
Shunt Anatomic Intrapulmonary • blood passes through an anatomic channel of the heart and does not pass through the lungs ex: ventricular septal defect • blood flows through pulmonary capillaries without participating in gas exchange ex: alveoli filled with fluid * Patients with shunts are more hypoxemic than those with VQ mismatch and they may require mechanical ventilators
Diffusion Limitation Gas exchange is compromised by a process that thickens or destroys the membrane Pulmonary fibrosis 2. ARDS * A classic sign of diffusion limitation is hypoxemia during exercise but not at rest
Alveolar Hypoventilation • Mainly due to hypercapnic respiratory failure but can cause hypoxemia • Increased pCO2 with decreased PO2 • Restrictive lung disease • CNS diseases • Chest wall dysfunction • Neuromuscular diseases
Hypercapnic Respiratory Failure • Abnormalities of the: • Airways and Alveoli-air flow obstruction and air trapping • Asthma, COPD, and cystic fibrosis • CNS-suppresses drive to breathe • drug OD, narcotics, head injury, spinal cord injury • Chest wall-Restrict chest movement • Flail chest, morbid obesity, kyphoscoliosis Neuromuscular Conditions- respiratory muscles are weakened: Guillain-Barre, muscular dystrophy, myasthenia gravis and multiple sclerosis
Tissue Oxygen needs • Tissue O2 delivery is determined by: • Amount of O2 in hemoglobin • Cardiac output • *Respiratory failure places patient at more risk if cardiac problems or anemia
Signs and Symptoms of Respiratory Failure • hypoxemia • pO2<50-60 • May be hypercapnia • pCO2>45-50 • only one cause- hypoventilation *In patients with COPD watch for acute drop in pO2 and O2 sats along with inc. C02
Specific Clinical Manifestations • Respirations- depth and rate • Patient position- tripod position • Pursed lip breathing • Orthopnea • Inspiratory to expiratory ratio (normal 1:2) • Retractions and use of accessory muscles • Breath sounds
Hypoxemia • Tachycardia and Hypertension to comp. • Dyspnea and tachypnea to comp. • Cyanosis • Restlessness and apprehension • Confusion and impaired judgment • Later dysrhythmias and metabolic acidosis, decreased B/P and CO.
Hypercapnia • Dyspnea to respiratory depression- if too high CO2 narcosis • Headache-vasodilation • Papilledema • Tachycardia and inc. B/P • Drowsiness and coma • Respiratory acidosis • **Administering O2 may eliminate drive to breathe especially with COPD patients
Diagnosis • Physical Assessment • Pulse oximetry • ABG • CXR • CBC • Electrolytes • EKG • Sputum and blood cultures, UA • V/Q scan if ?pulmonary embolus • Pulmonary function tests
Treatment • Goal- to correct Hypoxia • O2 therapy • Mobilization of secretions • Positive pressure ventilation(PPV) • Noninvasively( NIPPV) through mask • Invasively through oro or nasotracheal intubation
O2 Therapy • If secondary to V/Q mismatch- 1-3Ln/c or 24%-32% by mask • If secondary to intrapulmonary shunt- positive pressure ventilation-PPV • May be via ET tube • Tight fitting mask • Goal is PaO2 of 55-60 with SaO2 at 90% or more at lowest O2 concentration possible • O2 at high concentrations for longer than 48 hours causes O2 toxicity
Positive Pressure Ventilation • Noninvasive ( NIPPV) through mask • Used for acute and chronic resp failure • BiPAP- different levels of pressure for inspiration and expiration- (IPAP) higher for inspiration,(EPAP) lower for expiration • CPAP- for sleep apnea • Used best in chronic resp failure in patients with chest wall and neuromuscular disease, also with HF and COPD. NPPV
Drug Therapy • Relief of bronchospasm- • Bronchodilators • metaproterenol (Alupent) and albuterol-(Ventolin, Proventil, Proventil-HFA, AccuNeb, Vospire, ProAir ) • Watch for what side effect? • Reduction of airway inflammation • corticosteroids by inhalation or IV or po • Reduction of pulmonary congestion- • diuretics and nitroglycerine with heart failure
Drug Therapy • Treatment of pulmonary infections- • IV antibiotics- vancomycin and ceftriaxone (Rocephin) • Reduction of anxiety, pain and agitation • propofol (Diprivan), lorazepam (Ativan), midazolam (Versed), opioids • May need sedation or neuromuscular blocking agent if on ventilator • vecuronium (Norcuron), cisatracurium besylate (Nimbex ) • assess with peripheral nerve stim.
Medical Supportive Treatment • Treat underlying cause • Maintain adequate cardiac output- • monitor B/P and MAP. • **Need B/P of 90 systolic and MAP of 60 to maintain perfusion to the vital organs • Maintain adequate Hemoglobin concentration- • need 9g/dl or greater • Nutrition- • During acute phase- enteral or parenteral nurtition • In a hypermetabolic state- need more calories • If retain CO2- avoid high carb diet
Acute Respiratory FailureGerontologic Considerations • Physiologic aging results in • ↓ Ventilatory capacity • Alveolar dilation • Larger air spaces • Loss of surface area • Diminished elastic recoil • Decreased respiratory muscle strength • ↓ Chest wall compliance
Memory Jogger • Assault to the pulmonary system • Respiratory distress • Decreased lung compliance • Severe respiratory failure
150,000 adults develop ARDS • About 50% survive • Patients with gram negative septic shock and ARDS have mortality rate of 70-90%
Direct Causes • Inflammatory process is involved • Pneumonia* • Aspiration of gastric contents* • Pulmonary contusion • Near drowning • Inhalation injury
Indirect Causes • Inflammatory process is involved • Sepsis* (most common) gm - • Severe trauma with shock state that requires multiple blood transfusions* • Drug overdose • Acute pancreatitis
↓CO Metabolic acidosis ↑CO Interstitial & alveolar edema Severe & refractory hypoxemia *Causes (see notes) DIFFUSE lung injury (SIRS or MODS) Damage to alveolar capillary membrane Pulmonary capillary leak SHUNTING Stiff lungs Inactivation of surfactant Hyperventilation Hypocapnea Respiratory Alkalosis Alveolar atalectasis Hypoventilation Hypercapnea Respiratory Acidosis
Pathophysiology of ARDS • Damage to alveolar-capillary membrane • Increased capillary hydrostatic pressure • Decreased colloidal osmotic pressure • Interstitial edema • Alveolar edema or pulmonary edema • Loss of surfactant
Pathophysiologic Stages in ARDS • Injury or Exudative- 1-7 days • Interstitial and alveolar edema and atelectasis • Refractory hypoxemia and stiff lungs • Reparative or Proliferative-1-2 weeks after • Dense fibrous tissue, increased PVR and pulmonary hypertension occurs • Fibrotic-2-3 week after • Diffuse scarring and fibrosis, decreased surface area, decreased compliance and pulmonary hypertension
The essential disturbances of ARDS • Interstitial and alveolar edema and atelectasis • Progressive arterial hypoxemia in spite of inc. O2 is hallmark of ARDS
Clinical Manifestations: Early • Dyspnea-(almost always present), tachypnea, cough, restlessness • Lung sounds-may be normal or reveal fine, scattered crackles • ABGs -Mild hypoxemia and respiratory alkalosis caused by hyperventilation • Chest x-ray -may be normal or show minimal scattered interstitial infiltrates • Edema -may not show until 30% increase in lung fluid content
Clinical Manifestations: Late • Symptoms worsen with progression of fluid accumulation and decreased lung compliance • PFTs show decreased compliance and lung volume • Evident discomfort and increased WOB • Suprasternal retractions • Tachycardia, Diaphoresis • Changes in sensorium with decreased mentation, cyanosis, and pallor • Hypoxemia and a PaO2/FIO2 ratio <200 despite increased FIO2 ( ex: 80/.8=100)
Clinical Manifestations • As ARDS progresses, profound respiratory distress requires endotracheal intubation and positive pressure ventilation • Chest x-ray termed whiteout or white lung because of consolidation and widespread infiltrates throughout lungs
Clinical Manifestations • If prompt therapy not initiated, severe hypoxemia, hypercapnia, and metabolic acidosis may ensue
Diagnostic Tests • ABG • CXR • Pulmonary Function Tests • Hemodynamic Monitoring • ABG review • RealNurseEd (Education for Real Nurses by a Real Nurse)